argenx Announces Positive Topline Results from Phase 2 Study of FB102 in Celiac Disease

Impact · against what's priced in

Positive Phase 2 results for FB102 in celiac disease provide a catalyst for ARGX, as the market had previously declined to value the pipeline potential of the Forte Biosciences acquisition beyond the initial cost. While the move toward Phase 3 will increase R&D spend, the clinical validation of the CD122 mechanism improves the probability of success for other autoimmune targets.

ARGX+0.60

Challenges what's priced in

The price assumes